Clinical trials: Dengue Virus Infection
Dengue
Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
Dengue viruses can cause dengue fever and other serious health conditions, primarily affecting people living in tropical regions of the world.
- Trial name
- NCT01436422
- Testing
- TetraVax-DV Vaccine - Admixture TV003, TetraVax-DV Vaccine - Admixture TV005
- Where
- 3 sites in United States
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever
A Study to Monitor the Adverse Events of QDENGA Vaccine in Participants in Malaysia
The main aim of this study is to collect the number and type of medical problems (adverse events) after vaccination with QDENGA in Malaysia and to learn more about such medical problems after vaccination.
- Trial name
- PRIME-Q (NCT06388785)
- Testing
- No Intervention
- Where
- 2 sites in Malaysia
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Takeda
Arbovirus Infections, Dengue
Genetic Evolution of Arboviruses in New Caledonia Between 1995 and 2024 and Impact of Wolbachia
Arboviruses, diseases transmitted to humans by the bite of an insect vector, are a major public health problem, especially in tropical and sub-tropical countries.
- Conditions
- Arbovirus Infections, Dengue, Zika, Chikungunya
- Trial name
- DENWOLUTION (NCT04615364)
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Institut Pasteur
Dengue Vaccines
Characterisation of Dengue Vaccine-induced Specific Immunity in Vaccinees With and Without Prior Exposure to Flavivirus Infections or Vaccination
The goal of this observational study is to learn about the immunity induced by the Qdenga® vaccine in vaccinees. Participants that will receive the Dengue vaccine as part of their routine before a travel will be asked to undergo…
- Trial name
- VaQDENV (NCT06776692)
- Testing
- Qdenga
- Where
- Italy
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- IRCCS Sacro Cuore Don Calabria di Negrar
Dengue Fever
Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia
The primary objective of the study is to identify any suspected dengue case in subjects that received at least one dose of the CYD dengue vaccine who were classified as seronegative or undetermined at baseline (according to…
- Trial name
- CYD00082 (NCT04113330)
- Where
- Colombia
- Volunteers
- 918 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age
The aim of the study was to assess the immune response and the safety of different vaccination schedules of CYD dengue vaccine. The primary objectives of the study were: To demonstrate the non-inferiority of the immune response…
- Trial name
- NCT02628444
- Testing
- CYD Dengue Vaccine
- Where
- 6 sites in Colombia, Philippines
- Volunteers
- 1,050 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Diabetes, Hypercholesterolemia
Baromètre Santé Adulte 2021-2022
In 2021-2022, Agence Sanitaire et Sociale Nouvelle Calédonie (ASSNC) is undertaking the "Baromètre Santé Adulte" for the third time.
- Conditions
- Diabetes, Hypercholesterolemia, Renal Failure, Dengue Fever
- Trial name
- NCT05218304
- Testing
- Blood sample
- Where
- New Caledonia
- Volunteers
- 5,471 people, healthy volunteers welcome
- Sponsor
- Agence Sanitaire et Sociale de Nouvelle Calédonie
Viral Infection
Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects
The purpose of this study is to evaluate the safety and pharmacokinetics of UV-4B oral solution when administered to healthy subjects three times a day (TID) for 7 days.
- Trial name
- NCT02696291
- Testing
- UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution
- Where
- 2 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Emergent BioSolutions
Dengue
A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants
The main target populations for the tetravalent live attenuated dengue virus vaccine are indigenous populations, especially infants less than 2 years old, residing in areas of the world endemic for dengue and at risk of…
- Trial name
- NCT00322049
- Testing
- Tetravalent live attenuated dengue vaccine, Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine
- Where
- Thailand
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue
A Study of Balapiravir in Patients With Dengue Virus Infection
This randomized, double-blind, multiple-dose, placebo-controlled study will evaluate the safety, tolerability and efficacy of balapiravir in adult male patients with confirmed dengue virus infection whose symptoms began within…
- Trial name
- NCT01096576
- Testing
- balapiravir [RO4588161]
- Where
- Vietnam
- Volunteers
- 64 people
- Sponsor
- Hoffmann-La Roche
Dengue, Dengue With Warning Signs
Anakinra in Dengue With Hyperinflammation ( AnaDen )
This study aims to evaluate the effect of anakinra in dengue patients with hyperinflammation as compared to placebo Primary Objective: To evaluate the efficacy of Anakinra in moderate-severe dengue patients with…
- Conditions
- Dengue, Dengue With Warning Signs, Severe Dengue, Anakinra
- Trial name
- NCT05611710
- Testing
- Anakinra
- Where
- Vietnam
- Volunteers
- 160 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Dengue Fever
Zanamivir Treatment of Vascular Permeability in Dengue (ZAP-DENGUE)
ZAP-DENGUE is a pilot randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of five days of intravenous zanamivir treatment to treat vascular permeability syndrome which is the main cause of death in…
- Trial name
- ZAP-DENGUE (NCT04597437)
- Testing
- Zanamivir
- Where
- 2 sites in Colombia
- Volunteers
- 74 people
- Sponsor
- George Washington University
Dengue, Dengue Fever
Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study
The purpose of this study was to conduct a passive surveillance of hospitalized dengue cases in participants who participated in study CYD23 (NCT00842530).
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01983553
- Where
- Thailand
- Volunteers
- 3,203 people
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue
Clinical Bridging Study Between V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [Live, Attenuated]) to Butantan Dengue Vaccine (Butantan - DV) in Healthy Adults 18 to 50 Years of Age in Brazil (V181 - 002)
The purpose of this study was to demonstrate that V181 is safe and well tolerated and elicits an immune response that is non-inferior to that of Butantan - DV at Day 28 post-vaccination in adults 18 to 50 years of age in Brazil.
- Trial name
- NCT05710224
- Testing
- V181, Butantan - DV
- Where
- 14 sites in Brazil
- Volunteers
- 1,364 people, healthy volunteers welcome
- Sponsor
- Butantan Institute
Dengue Fever, Zika
Sylvatic Transmission of Zika, Dengue, and Chikungunya Viruses in Thailand and Cambodia
Background: Zika, dengue, and chikungunya are spread by mosquitos. These diseases have a major impact on public health. This is especially true in in Southeast Asia.
- Conditions
- Dengue Fever, Zika, Vector-Borne Diseases, Chikungunya
- Trial name
- NCT04434846
- Where
- Cambodia
- Volunteers
- 300 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue Fever
Safety and Immune Response to Two Doses of rDEN2/4delta30 Dengue Vaccine
Dengue fever, caused by dengue viruses, is a major health problem in the tropical and subtropical regions of the world. The purpose of this study is to test the safety of and immune response to a new dengue virus vaccine in…
- Trial name
- NCT00920517
- Testing
- rDEN2/4delta30(ME) vaccine
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Evaluation of T-cell Responses After Vaccination With the Attenuated Tetravalent Dengue Vaccine (Takeda).
Dengue is one of the most epidemiologically and clinically relevant arboviral diseases, affecting half of the global population.
- Trial name
- RIMVADE (NCT07158190)
- Testing
- Vaccine
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Dengue
Dengue - Sample Collection Study Pakistan
The objective of this study is to collect well-characterized serum and plasma specimens from confirmed dengue positive and dengue negative subjects to support dengue diagnostic products development.
- Trial name
- NCT07203183
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Abbott Rapid Dx
Dengue Fever
Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV)
The purpose of this study is to evaluate the equivalence of the lyophilized formulation of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) compared with the liquid formulation of TDV.
- Trial name
- NCT02193087
- Testing
- TDV Liquid Formulation 1, TDV Liquid Formulation 2, TDV IDT Lyophilized
- Where
- 7 sites in United States
- Volunteers
- 1,002 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever
Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity
This study assessed the safety and immunogenicity of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) previously referred to as DENVax of various dosing schedules via subcutaneous (SC) or intramuscular (IM) administration with…
- Trial name
- NCT01728792
- Testing
- TDV
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Takeda